Articles related to BIOMARKERS

Changes to blood-based biomarkers can be detected before Alzheimer’s symptoms appear, potentially allowing for earlier intervention and more targeted treatment approaches.

The study found no evidence that any of 25 routine clinical laboratory values provide a reliable biomarker of prior infection, PASC, or specific PASC clusters.

MCED tests aim to detect multiple cancer types through a single blood test, potentially simplifying cancer screening and expanding detection capabilities. However, their implementation raises critical questions about evidence standards and evaluation methods.

An innovative blood test using artificial intelligence has shown the potential to detect Parkinson’s disease up to seven years before symptoms appear, offering new possibilities for early intervention and treatment.

In this study, dostarlimab combined with carboplatin-paclitaxel demonstrated a marked improvement in progression-free and overall survival among endometrial cancer patients, particularly those with genetic markers for dMMR and MSI-H.

As physicians, understanding the new biomarker legislation is crucial—it not only shapes insurance coverage but also influences clinical decision-making and patient access to precision medicine, potentially leading to more cost-effective and targeted care.